相关实验视频

Updated: Mar 8, 2026

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport

Published on: November 27, 2016

在威尔逊病时,FXR-cistrome的变化和胆酸生理学的改变

Clavia Ruth Wooton-Kee^1,2, Hari K Yalamanchili^1,3, Islam Mohamed⁴

¹Department of Pediatrics-Nutrition, Children's Nutrition Research Center, Baylor College of Medicine, Houston, Texas, USA.

Hepatology communications

|May 23, 2025

概括

威尔逊病 (WD) 涉及铜过载和肝损伤. 这项研究发现,Farnesoid X受体 (FXR) 在小鼠肝脏中结合的变化,影响了WD中的胆酸代谢和细胞应激通路.

科学领域:

肝病学和代谢疾病
分子生物学和遗传学

背景情况:

威尔逊病 (WD) 是一种遗传性疾病,导致肝脏过度积聚铜,导致严重的肝损伤.
以前的研究表明,WD中代谢基因的调节失调,包括那些由Farnesoid X受体 (FXR) 控制的基因.

研究的目的:

为了调查假设,在WD小鼠模型中,FXR-cistrome (基因组结合点) 被减少.
了解FXR在胆酸平衡和细胞应激中的作用,在WD的背景下.

主要方法:

利用Atp7b-/-小鼠作为威尔逊病的模型,分析肝脏组织中的FXR结合模式.
在WD小鼠和野生类型对照之间的促进器和远端跨基因区域中比较FXR占用率.
在WD小鼠和人类患者的血清和肝脏中分析了胆酸概况.

主要成果:

结合FXR显示了WD小鼠肝脏的复杂变化,促进器区域的占用率下降,远端跨基因区域的结合增加.
在帕伦基马细胞中,FXR活性降低,但在非帕伦基马细胞中增加,影响新陈代谢和压力路径.
与对照组相比,WD小鼠和WD患者均表现出血清和肝胆酸度升高.

结论:

在整个基因组中确定了新的FXR结合模式,突出显示了WD期间对外和非对外细胞的复杂调节.
改变的FXR活性和胆酸代谢是WD在小鼠模型和人类患者中的重要特征.

关键词:

在 FXR 和 FXR 之间.威尔逊病是威尔逊病的一种疾病.胆汁酸胆汁酸胆汁酸铜铜铜铜的铜.核受体是一种核受体.

更多相关视频

Ileectomy-induced Bile Overaccumulation in Mouse Intestine

Ileectomy-induced Bile Overaccumulation in Mouse Intestine

Published on: August 21, 2017

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

相关概念视频

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...

Chronic Bowel Disorders: Introduction

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Cystic Fibrosis: Pathogenesis

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...